CGS 0.50% 99.0¢ cogstate ltd

woosh,,,,,,,,,,, page-5

  1. hi
    279 Posts.
    cgs completes over $180,000 in sales since aug CogState Ltd
    www.cogstate.com
    8th September 2004
    CogState Completes Over $180,000 in Sales Since August
    As an update for shareholders, CogState Limited (ASX:CGS) announced today it has
    achieved significant revenue growth in the first ten weeks of the financial year – with more
    than $180,000 of sales of its diagnostic test for dementia and sports-related concussion
    management.
    These deals have been signed with major companies and organizations such as the
    Centers for Disease Control in the US and Pfizer.
    The revenue resulting from these deals, which equates to almost 98% of sales revenue
    for the previous financial year, has been achieved in the first 10 weeks of this financial
    year (2004: $192,094) and indicates that CogState is on track for a healthy growth in
    revenues for the 2004-2005 year, according to Dr Peter Bick, CEO of CogState.
    The deals, which will generate the following revenue for CogState this financial year,
    are as follows:
    Date of
    Agreement
    Contracting Party Details Revenue
    to
    CogState
    Total
    2004
    Revenue
    16 Aug 2004 Centres for Disease
    Control and
    Prevention (Atlanta)
    Trial of HIV patients to spot early
    signs of HIV-related dementia
    $21,000
    25 Aug 2004 Pfizer Inc. Interim Agreement in respect of
    Phase III clinical trial
    $70,000
    16 Aug 2004 England Rugby
    Football Union
    Testing services for the year to 30
    June 2005.
    $37,000
    8 Sept 2004 Pfizer Inc. Phase I clinical trial $60,000
    Total $188,000 $192,094
    All revenue from the above contracts will be booked by CogState prior to 30 June 2005.
    Other Significant Revenue Raising Achievements:
    In addition to the above sales, CogState has also, since 1 July 2004, announced:
    • The signing of a Master Service Agreement with Pfizer Inc., which will provide the
    contractual basis for Pfizer’s future use, during clinical trials, of CogState’s
    computerized cognitive tests.
    • The signing (on 21 July, 2004) of a deal with major US sporting goods manufacturer,
    Schutt Sports, that will see the CogState diagnostic test, branded Concussion Sentinel
    for the US market, given away free to every College and High School in the USA for
    one year.
    The agreement with Schutt Sports and the associated “give away” has already received
    extensive media coverage in the USA, including the following:
    • USA Today – July 27th, 2004
    • Fox SportsNet – July 27th, 2004
    • CNN headline News – August 13th, 2004
    Advertising and promotion of the Concussion Sentinel product is continuing and the team
    at CogState are focused on signing new customers whilst the product is given away free
    so that next year our large base of experienced users will make the choice to renew or
    not rather than the tougher decision to purchase.
    About CogState: CogState Ltd. was established in 1999 with headquarters in Melbourne, Australia. In
    February 2004 the company listed on the Australian Stock Exchange (ASX) as “CGS.” The company
    specializes in neuroscience, particularly in the development and commercialization of computer-based tests
    for neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease and concussion-related injury.
    A division of the company, CogSport, marketed in the U.S. through a partnership with Schutt Sports (the
    worlds largest manufacturer of American Football helmets as Concussion Sentinel, is a novel concussion
    management tool developed to aid physicians in making confident return-to-play decisions after an athlete
    has suffered a concussion. Concussion Sentinel is applicable for use by sporting organizations, medical
    professionals, and parents/athletes and provides rapid measurement of cognitive function. Other divisions of
    the company focus on providing computer-based measurement tools to pharmaceutical companies for use
    during clinical trials. CogState also has a therapeutics division which has in-licensed two drug targets from
    leading medical research organisations in Japan and Israel for the treatment of Alzheimer's Disease and
    Parkinson's Disease respectively.
    For more information call Dr. Peter Bick on 0408 415 823 or visit
    www.cogstate.com
 
watchlist Created with Sketch. Add CGS (ASX) to my watchlist
(20min delay)
Last
99.0¢
Change
-0.005(0.50%)
Mkt cap ! $171.0M
Open High Low Value Volume
99.0¢ 99.5¢ 97.5¢ $128.0K 129.2K

Buyers (Bids)

No. Vol. Price($)
1 10000 99.0¢
 

Sellers (Offers)

Price($) Vol. No.
$1.02 1099 1
View Market Depth
Last trade - 16.10pm 19/11/2024 (20 minute delay) ?
CGS (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.